- Home
- BEAM vs SONO Comparison
BEAM vs SONO Comparison
Compare BEAM & SONO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- SONO
- Stock Information
- Founded
- BEAM 2017
- SONO 2002
- Country
- BEAM United States
- SONO United States
- Employees
- BEAM N/A
- SONO N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- SONO Consumer Electronics/Video Chains
- Sector
- BEAM Health Care
- SONO Consumer Discretionary
- Exchange
- BEAM Nasdaq
- SONO Nasdaq
- Market Cap
- BEAM 2.3B
- SONO 2.0B
- IPO Year
- BEAM 2020
- SONO 2018
- Fundamental
- Price
- BEAM $23.23
- SONO $16.37
- Analyst Decision
- BEAM Strong Buy
- SONO Strong Buy
- Analyst Count
- BEAM 11
- SONO 3
- Target Price
- BEAM $49.40
- SONO $17.00
- AVG Volume (30 Days)
- BEAM 2.6M
- SONO 1.4M
- Earning Date
- BEAM 11-04-2025
- SONO 11-05-2025
- Dividend Yield
- BEAM N/A
- SONO N/A
- EPS Growth
- BEAM N/A
- SONO N/A
- EPS
- BEAM N/A
- SONO N/A
- Revenue
- BEAM $55,701,000.00
- SONO $1,443,276,000.00
- Revenue This Year
- BEAM N/A
- SONO $2.89
- Revenue Next Year
- BEAM $19.01
- SONO $8.55
- P/E Ratio
- BEAM N/A
- SONO N/A
- Revenue Growth
- BEAM N/A
- SONO N/A
- 52 Week Low
- BEAM $13.53
- SONO $7.63
- 52 Week High
- BEAM $35.25
- SONO $18.06
- Technical
- Relative Strength Index (RSI)
- BEAM 42.93
- SONO 47.25
- Support Level
- BEAM $26.90
- SONO $15.88
- Resistance Level
- BEAM $26.17
- SONO $17.89
- Average True Range (ATR)
- BEAM 1.84
- SONO 0.69
- MACD
- BEAM -0.68
- SONO -0.16
- Stochastic Oscillator
- BEAM 11.47
- SONO 22.39
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.